

PATENT SPECIFICATION

(11) 1 432 649

1 432 649

- (21) Application No. 42173/73 (22) Filed 7 Sept. 1973
 (23) Complete Specification filed 23 July 1974
 (44) Complete Specification published 22 April 1976
 (51) INT CL² C07D 237/28; A61K 31/495; C07D 491/04/(C07D 491/04, 237/28, 317/48)
 (52) Index at acceptance
 C2C 134X 1504 1592 1772 200 213 215 21X 220 226 22Y 246
 247 250 251 252 255 25Y 305 30Y 351 352 364 366
 368 36Y 386 387 388 389 40Y 491 624 625 628 635
 658 65X 662 672 699 760 761 762 776 778 790 79Y
 TR TY WD ZG
 A5B 292 295 29Y 383 386 38Y 39X 441 44Y 482 48Y 503
 50Y 550 552 55Y 575 576 57Y 586 58Y 616 61Y 640
 644 64Y 661 66Y 77Y
 (72) Inventor GERAINT JONES




(54) NEW CINNOLINE DERIVATIVES AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS

(71) We, IMPERIAL CHEMICAL INDUSTRIES LIMITED, Imperial Chemical House, Millbank, London SW1P 3JF, a British Company, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—

This invention relates to heterocyclic compounds, and more particularly it relates to new cinnoline derivatives which are active as inhibitors of the effects following the combination of reagin-like antibodies and their antigens.

According to the invention there are provided cinnoline derivatives of the formula:—




wherein R¹ stands for hydrogen or a C₁₋₆-alkyl radical, R² stands for hydrogen or a C₁₋₃-alkyl, C₃₋₅-alkenyl or benzyl radical, and R³ stands for hydrogen or a methylenedioxy, C₁₋₃-alkyl, C₁₋₃-alkoxy, phenyl or benzyloxy radical, and non-toxic pharmaceutically-acceptable salts thereof.

Suitable values for R¹ are, for example, hydrogen or a methyl, ethyl or isopropyl radical. Suitable values for R² are, for example, hydrogen or a methyl, ethyl, allyl or benzyl radical. Suitable optional substituents (R³) include, for example, a methylenedioxy, methyl, ethyl, n-propyl, isopropyl, methoxy, isopropoxy, phenyl or benzyloxy radical. It is to be understood that the two bonds of the methylenedioxy radical (R³) are attached to adjacent carbon atoms of the benzene ring.

Suitable salts of the invention in the case where the compound of the formula I is sufficiently basic are acid-addition salts derived from inorganic or organic acids which afford non-toxic pharmaceutically-acceptable anions, for example hydrochlorides. Suitable salts in the case where the compound of the formula I is sufficiently acidic are salts in which the said compound provides the anion and the cation is non-toxic and pharmaceutically-acceptable. Examples of such salts are ammonium, alkali metal, alkaline earth metal or aluminium salts, or salts with non-toxic pharmaceutically-acceptable organic bases, for example triethanolamine or ethylenediamine.

Preferred compounds of the invention are ethyl 6-ethyl-1-methyl-4-oxo-1,4-dihydrocinnolin-3-ylpropionate, 6-ethyl-4-oxo-1,4-dihydrocinnoline-3-ylpropionic acid and its ethyl ester, and 6-n-propyl-4-oxo-1,4-dihydrocinnolin-3-ylpropionic acid.


According to a further feature of the invention there is provided a process for the manufacture of those of the compounds of the formula I wherein R^1 and R^2 stand for hydrogen and R^3 has the meaning stated above, and non-toxic pharmaceutically-acceptable salts thereof, which comprises reacting a benzazocine derivative of the formula:—



wherein R^3 has the meaning stated above, with an alkyl nitrite and an inorganic acid in the presence of a small amount of water.

A suitable alkyl nitrite is, for example, n-butyl nitrite. A suitable acid is, for example, hydrochloric or sulphuric acid. The reaction is conveniently carried out in an inert organic solvent, for example an ether, for example 1,2-dimethoxyethane. The amount of water used in the reaction mixture is not critical; we have found that approximately 0.5—0.6% by volume gives satisfactory results.

Many of the said benzazocine derivatives are new compounds and they may be obtained by the following reactions:—




The phenylhydrazine derivatives (III), wherein R^3 has the meaning stated above, may be obtained by standard synthetic procedures. Heating one of these compounds with cyclopentanone (IV) in the presence of dilute sulphuric acid, or heating the hydrochloride of one of these phenylhydrazine derivatives with cyclopentanone, affords the corresponding indole derivative of the formula V. Treatment of the latter compound at room temperature with sodium periodate in a mixture of methanol and water, together with tetrahydrofuran if there are solubility problems, affords the product of the formula II.

According to a further feature of the invention there is provided a process for the manufacture of the esters of the formula I wherein R^1 stands for a C_{1-6} -alkyl radical, R^2 stands for hydrogen, and R^3 has the meaning stated above, and non-toxic pharmaceutically-acceptable salts thereof, which comprises esterifying the corresponding carboxylic acid wherein R^1 stands for hydrogen, or a corresponding acid halide or anhydride.

Any of the standard esterification procedures may be used, for example reacting the carboxylic acid with a C_{1-6} -alcohol in the presence of hydrogen chloride at about 50 to 150°C., for example under reflux.


According to a further feature of the invention there is provided a process for the manufacture of those of the compounds of the formula I wherein R^1 stands for a C_{1-6} -alkyl radical, R^2 stands for C_{1-3} -alkyl, C_{3-5} -alkenyl or benzyl radical, and R^3 has the meaning stated above, and non-toxic pharmaceutically-acceptable salts thereof, which comprises reacting an alkali metal derivative of the formula:—



wherein R^1 and R^3 have the meanings stated immediately above and M stands for a sodium or potassium atom, with a halide reactant of the formula $R^2\text{Hal}$, wherein R^2 has the meaning stated immediately above and Hal stands for a chlorine, bromine or iodine atom.

As a suitable halide reactant there may be mentioned, for example, methyl iodide, ethyl bromide, allyl bromide or benzyl chloride. The reaction is conveniently carried out in an organic solvent, for example dimethylformamide, at room temperature or at a moderately elevated temperature, for example 60—70°C. The alkali metal derivatives used as starting material may be obtained by reacting the corresponding compound wherein R^2 stands for hydrogen with the hydride or amide of sodium or potassium, in a dry inert solvent, for example dimethylformamide, at room temperature.

The compounds of the formula I wherein R^1 stands for hydrogen and R^2 and R^3 have the meaning stated above, and non-toxic pharmaceutically-acceptable salts thereof, may be obtained by hydrolysing a compound of the formula:—



wherein R^2 and R^3 have the meanings stated above and Cy stands for an alkoxycarbonyl, phenylalkoxycarbonyl, phenoxy carbonyl, cyano, carbamoyl (—CONH₂) or thiocarbamoyl (—CSNH₂) radical.

The hydrolysis is carried out in the presence of water. An organic solvent, for example dioxan or ethanol, may optionally also be present. A suitable hydrolytic agent is, for example, an alkali metal hydroxide, for example sodium hydroxide, or an inorganic acid, for example hydrochloric or sulphuric acid.

The esters of the formula VII may be obtained as described above, and the other starting materials of the formula VII may be obtained by the adaptation of known synthetic procedures.

The salts of this invention may be obtained by means of standard salt-making procedures.

The above-mentioned activity of the compounds of this invention has been demonstrated by their ability to inhibit, in the rat, passive cutaneous anaphylaxis induced by reaginic antibodies to egg albumin, using *B. pertussis* as an adjuvant. This is a known pharmacological test. The activity of individual compounds of this invention in the test depends upon their precise chemical structure, but generally speaking the compounds show activity in the test at a dose in the region 1—20 mg./kg. No toxic effects or undesirable side effects have been observed with the compounds at doses at which they are active in the said test.

When a compound of the invention is used in a warm-blooded mammal, for example man, for the treatment of a disease or syndrome which is initiated by an antigen-antibody reaction, for example allergic asthma, hay fever, urticaria or an auto-immune disease, it is recommended that said compound be administered orally or by inhalation at a dose of 0.01 mm./kg. to 1 mm./kg. at appropriate intervals, for example at 6-hourly intervals during the day. Alternatively, the said compound may be administered intravenously at a total daily dose of about 25 mg. per man.

According to a further feature of the invention there are provided pharmaceutical compositions comprising a compound of the formula I, wherein R^1 , R^2 and R^3 have the meanings stated above, or a non-toxic pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable diluent or carrier.

The pharmaceutical compositions of the invention are obtainable by well known methods using conventional diluents or carriers. The compositions may be in a form suitable for administration by inhalation. Suitable compositions comprise a mixture of the active ingredient with a solid diluent or carrier, for example lactose, the said mixture being in fine particulate form suitable for administration from a powder inhalation device. Alternatively, the compositions may be administered by inhalation in the form of a suspension or solution in a suitable liquid, for example water or an aqueous or non-aqueous medium, using a conventional nebulizer or a pressurised container. Alternatively, the pharmaceutical compositions of the invention may be orally-administrable or

injectable formulations, for example compositions suitable for oral or intravenous administration, for example tablets, capsules or sterile aqueous solutions or suspensions.

5 The pharmaceutical compositions of the invention may contain, in addition to a compound of formula I or a non-toxic pharmaceutically-acceptable salt thereof, one or more known active ingredients selected from β -adrenergic stimulants, for example isoprenaline, adrenaline, orciprenaline or isoethacine, or a pharmaceutically-acceptable acid-addition salt thereof, for example a sulphate, and prostaglandins having bronchodilatory activity, for example prostaglandin E_1 or E_2 , and phosphodiesterase inhibitors selected from the following compounds:—

- 10 (a) 3 - acetamido - 6 - methyl - 8 - n - propyl - s - triazolo[4,3-a] - pyrazine;
 (b) 2 - amino - 4,6 - di - C_{1-4} - alkyl - 5 - oxo - 4,5 - dihydro - triazolo[1,5 - a] - pyrimidines, for example 2 - amino - 6 - methyl - 5 - oxo - 4 - n - propyl - 4,5 - dihydro - s - triazolo[1,5-a]pyrimidine;
 15 (c) theophylline and related 3,5 - di - C_{1-4} - alkyl - xanthines; and
 (d) 6,8 - di - C_{1-4} - alkyl - 5,6 - dihydro - 5 - oxo - triazolo[4,3-c]pyrimidines, for example 5,6 - dihydro - 5 - oxo - 6,8 - di - n - propyl - s - triazolo-[4,3-c]pyrimidine.


20 The pharmaceutical compositions of the invention may contain from 1% to 50% by weight of a compound of formula I or a non-toxic pharmaceutically-acceptable salt thereof.

The invention is illustrated by the following Examples:—

Example 1.

25 A suspension of 4,5-dihydro-1H,3H-1-benzazocine-2,6-dione (1 g.) in 1,2-dimethoxyethane (20 ml.) and water (0.1 ml.) was prepared, and freshly-prepared n-butyl nitrite (0.84 g.) was added. Hydrogen chloride gas was bubbled through the mixture at 25°C. for 5 minutes, and the resulting solution was stirred overnight at room temperature. The solution was then diluted with water (10 ml.), the mixture warmed for 5 minutes on a steam bath, and the resulting mixture filtered. The solid residue was recrystallised from aqueous ethanol, and there was thus obtained 4-oxo-1,4-dihydrocinnolin-3-ylpropionic acid, m.p. 226—8°C.

30 In a similar manner, using the appropriate substituted benzazocine derivative as starting material, the following compounds were obtained:—



R^3	Crystallisation solvent	m.p. (°C.)
6-Et	aqueous ethanol	240—1
6-n-Pr	aqueous acetic acid	230—1
6-iso-Pr	product not crystallised, but isolated by acidification of sodium salt with concentrated hydrochloric acid	228—30
6-PhCH ₂ O	ethanol	245—7
6-MeO	aqueous ethanol	256—8
6-iso-PrO	aqueous acetic acid	210—3
6-Ph	aqueous acetic acid	306—10 (dec.)

The 8-ethyl-4,5-dihydro-1H,3H-1-benzazocine-2,6-dione used as starting material for the preparation of the above-mentioned 6-ethyl derivative was obtained as follows:—


- (a) To a suspension of 4-ethylaniline (90 g.) in water (280 ml.) was added concentrated hydrochloric acid (38% w/w, 280 ml.), and the mixture was warmed on a steam bath. The suspension obtained was stirred and cooled to 0°C., and a solution of sodium nitrite (52.1 g.) in water (180 ml.) was added during 45 minutes, the temperature being maintained at -10° to -5°C. by cooling. The dark solution was stirred at 0°C. for a further 30 minutes, and then filtered through "Celite" (the word 'Celite' is a registered Trade Mark). The filtered diazonium salt solution (stored at 0°C.) was added in portions to a stirred fresh mixture of sodium dithionite (500 g.) in ice-cold water (1 l.) keeping the temperature at 5—10°C. After the addition of each batch of the diazonium salt solution, further dithionite (total 500 g.) was added in portions. After the addition was complete (45 minutes), the mixture was stirred at room temperature overnight. The mixture was separated by filtration and the filtered solid was suspended in water (1 l.), basified with sodium hydroxide solution, and the mixture extracted with ethyl acetate (3 × 250 ml.). The combined extracts were washed with a minimum of water, dried (MgSO₄), and evaporated to give 4-ethylphenylhydrazine as a low melting solid.
- (b) The above hydrazine derivative (80 g.) and cyclopentanone (50 g.) were mixed and heated on a steam bath for 15 minutes. A solution of concentrated sulphuric acid (40 ml.) in water (720 ml.) was added and the mixture was heated for a further 30 minutes. After cooling in an ice-bath, the black solid which separated was filtered off. A solution of the solid in toluene (750 ml.) was dried (MgSO₄) and filtered, and the filtrate was concentrated. The residue was applied to a silica gel column (1000 g.) Elution with toluene and concentration of the eluate gave 7-ethyl-1,2,3,4-tetrahydrocyclopentan[b]indole, m.p. 74—9°C.
- (c) A solution of the above-mentioned indole derivative (50 g.) in methanol (1360 ml.) was added to a solution of sodium periodate (126 g.) in water (728 ml.) at room temperature. The solution became warm, and sodium iodate appeared as white needles. After 2 hours the mixture was diluted with water (500 ml.) and extracted with methylene dichloride (4 × 150 ml.). The combined extracts were washed with water (2 × 100 ml.), dried (MgSO₄), filtered, and evaporated to dryness. Crystallisation of the residue from toluene (including treatment with charcoal) gave 8-ethyl-4,5-dihydro-1H,3H-1-benzazocine-2,6-dione, m.p. 138—140°C.
- The 8-benzyloxy-4,5-dihydro-1H,3H-1-benzazocine-2,6-dione used as starting material for the preparation of the above-mentioned 6-benzyloxy-4-oxo-1,4-dihydrocinnolin-3-ylpropionic acid was obtained as follows:—
- (d) A solution of 4-benzyloxyphenylhydrazine hydrochloride (50.2 g.) and cyclopentanone (33.6 g.) in ethanol (150 ml.) was heated on a steam bath for 5 hours. The hot mixture was filtered and the filtrate evaporated to ca 750 ml., whereupon 7-benzyloxy-1,2,3,4-tetrahydrocyclopentan[b]indole, m.p., 110—2°C., crystallised. Evaporation of the mother liquor to dryness, chromatography of the residue on silica gel (600 g.), and elution with toluene, gave a further amount of the product, m.p. 114°C.
- (e) A solution of the said 7-benzyloxy derivative (17.5 g.) in methanol (250 ml.) and tetrahydrofuran (100 ml.) was added to a solution of sodium periodate (28 g.) in water (130 ml.) at room temperature. The solution became warm and sodium iodate appeared as white needles. After 2 hours the solution was diluted with water (500 ml.) and extracted with methylene chloride (4 × 150 ml.). The combined extracts were washed with water (2 × 100 ml.), dried (MgSO₄), filtered, and evaporated. Crystallisation of the residue from toluene (including treatment with charcoal) gave 8-benzyloxy-4,5-dihydro-1H,3H-1-benzazocine-2,6-dione, m.p. 169—70°C.
- The other benzazocine derivatives used as starting materials were obtained in similar manner. As indicated below, in one case the indole intermediate was obtained by procedure (b) above, and in the other cases by procedure (d) above, while in one case the benzazocine derivative was obtained by procedure (e) above, and in the other cases by procedure (c) above.

Substituent in benzene ring	Indole derivative— procedure used	Benzazocine derivative— procedure used
n-Pr	d	c
iso-Pr	d	c
MeO	d	c
iso-PrO	d	c
Ph	b	e

Example 2.

A suspension of 6-methyl-4-oxo-1,4-dihydrocinnolin-3-ylpropionic acid (1 g.) in methanol (10 ml.) was heated under reflux. Hydrogen chloride gas was bubbled through the mixture under reflux for 30 minutes. The mixture was then heated under reflux overnight. The mixture was cooled and diluted with water (50 ml.). The resulting mixture was filtered, and the solid residue was recrystallised from methanol. There was thus obtained methyl 6-ethyl-4-oxo-1,4-dihydrocinnolin-3-ylpropionate, m.p. 173—4°C.

In a similar manner, starting with the appropriate propionic acid, there were obtained the following compounds:—




R ¹	R ³	Crystallisation solvent	m.p. (°C.)
Et	6-Et	acetonitrile	179—80
iso-Pr	6-Et	„	182—3
Et	6-n-Pr	„	175—7
Et	6-iso-Pr	„	155—60 (dec.)
Me	6-iso-PrO	„	205—7
Et	6-iso-PrO	„	184—6
Et	6,7-OCH ₂ O	„	231—3
Me	6-Ph	methanol	255—7
Et	6-Ph	ethanol	202—3

Some of the propionic acids used as starting materials were obtained as described in Example 1, and the remainder were obtained by similar procedures.

Example 3.

Sodium hydride in oil (0.33 g.) was washed free from oil with petroleum ether (b.p. 40—60°C.; x 5 ml.) and then suspended in dimethylformamide (10 ml.) Ethyl 6-ethyl-4-oxo-1,4-dihydrocinnolin-3-ylpropionate (1 g.) was added, and the mixture was stirred at room temperature for 15 minutes. Methyl iodide (0.5 ml.) was added, and the mixture was stirred at 60—70°C. for 2 hours. The mixture was cooled and poured into water (100 ml.), and the resulting mixture was filtered. The solid residue was crystallised from petroleum ether (b.p. 60—80°C.), and there was thus obtained ethyl 6-ethyl-1-methyl-4-oxo-1,4-dihydrocinnolin-3-ylpropionate, m.p. 92—94°C.

The following compounds were obtained in a similar manner from the appropriate starting materials, except that, when the reaction mixture was poured into water (100 ml.), instead of being filtered, the mixture was extracted with diethyl ether (3 x 100 ml.), the combined extracts washed with saturated sodium chloride solution (100 ml.), dried (MgSO₄) and evaporated to dryness. The residue was crystallised using the solvents stated below. In this way, the following compounds were obtained:—




R ¹	R ²	R ³	Crystallisation solvent	m.p. (°C.)
Et	allyl	6-Et	pet. ether (b.p. 80—100°C.)	80—2
Et	Et	6,7-OCH ₂ O	toluene-pet. ether (b.p. 60—80°C.)	125—7
Me	Me	6-Ph	ethyl acetate-pet. ether (b.p. 60—80°C.)	130—2
Me	Me	6-iso-Pro	toluene-pet. ether (b.p. 60—80°C.)	124—6
Et	PhCH ₂	6-Et	pet. ether (b.p. 60—80°C.)	110—2

20

WHAT WE CLAIM IS:—

1. A cinnoline derivative of the formula:—

20



wherein R¹ stands for hydrogen or a C₁₋₆-alkyl radical, R² stands for hydrogen or a C₁₋₃-alkyl, C₃₋₃-alkenyl or benzyl radical, and R³ stands for hydrogen or a methylenedioxy, C₁₋₃-alkyl, C₁₋₃-alkoxy, phenyl or benzyloxy radical, or a non-toxic pharmaceutically-acceptable salt thereof.

25

25


2. A compound as claimed in claim 1 wherein R^1 stands for hydrogen or a methyl, ethyl or isopropyl radical, R^2 stands for hydrogen or a methyl, ethyl, allyl or benzyl radical, and R^3 stands for hydrogen or a methylenedioxy, methyl, ethyl, n-propyl, isopropyl, methoxy, isopropoxy, phenyl or benzyloxy radical.

3. A salt as claimed in claim 1 or 2 in the case where the compound of the formula I is sufficiently basic, which salt is an acid-addition salt derived from an inorganic or organic acid which affords a non-toxic pharmaceutically-acceptable anion.

4. A salt as claimed in claim 1 or 2 in the case where the compound of the formula I is sufficiently acidic, in which salt the acid compound of the formula I provides the anion, and the cation is non-toxic and pharmaceutically-acceptable.

5. A compound as claimed in claim 1 or 2 which is either ethyl 6-ethyl-1-methyl-4-oxo-1,4-dihydrocinnolin-3-ylpropionate, 6-ethyl-4-oxo-1,4-dihydrocinnolin-3-ylpropionic acid or its ethyl ester, or 6-n-propyl-4-oxo-1,4-dihydrocinnolin-3-ylpropionic acid.


6. A process for the manufacture of a compound of the formula I as stated in claim 1, wherein R^1 and R^2 stand for hydrogen and R^3 has the meaning stated in claim 1, or a non-toxic pharmaceutically-acceptable salt thereof, which comprises reacting a benzazocine derivative of the formula:—



wherein R^3 has the meaning stated in claim 1, with an alkyl nitrite and an inorganic acid in the presence of a small amount of water.

7. A process for the manufacture of a compound of the formula I as stated in claim 1, wherein R^1 stands for a C_{1-6} -alkyl radical, R^2 stands for hydrogen and R^3 has the meaning stated in claim 1, or a non-toxic pharmaceutically-acceptable salt thereof, which comprises esterifying the corresponding carboxylic acid wherein R^1 stands for hydrogen, or a corresponding acid halide or anhydride.

8. A process for the manufacture of a compound of the formula I as stated in claim 1, wherein R^1 stands for a C_{1-6} -alkyl radical, R^2 stands for a C_{1-5} -alkenyl or benzyl radical, and R^3 has the meaning stated in claim 1, or a non-toxic pharmaceutically-acceptable salt thereof, which comprises reacting an alkali metal derivative of the formula:—



wherein R^1 and R^3 have the meanings stated above and M stands for a sodium or potassium atom, with a halide reactant of the formula $R^2\text{Hal}$, wherein R^2 has the meaning stated above and Hal stands for a chlorine, bromine or iodine atom.

9. A pharmaceutical composition comprising a compound of the formula I as stated in claim 1, wherein R^1 , R^2 and R^3 have the meanings stated in claim 1, or a non-toxic pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable diluent or carrier.

10. A compound as claimed in claim 1, substantially as described in any of the foregoing Examples.

R. ALLERTON,
Agent for the Applicants.